Published in J Hypertens on November 01, 2003
Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Exp Physiol (2011) 1.99
Nuclear-delimited angiotensin receptor-mediated signaling regulates cardiomyocyte gene expression. J Biol Chem (2010) 1.24
Candesartan pretreatment is cerebroprotective in a rat model of endothelin-1-induced middle cerebral artery occlusion. Exp Physiol (2009) 1.20
Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol Neurodegener (2007) 1.05
Anti-inflammatory effects of angiotensin-(1-7) in ischemic stroke. Neuropharmacology (2013) 1.04
Direct angiotensin AT2 receptor stimulation using a novel AT2 receptor agonist, compound 21, evokes neuroprotection in conscious hypertensive rats. PLoS One (2014) 0.90
Attenuation of focal cerebral ischemic injury following post-ischemic inhibition of angiotensin converting enzyme (ACE) activity in normotensive rat. Iran Biomed J (2012) 0.86
Brain-Derived Neurotrophic Factor Knockdown Blocks the Angiogenic and Protective Effects of Angiotensin Modulation After Experimental Stroke. Mol Neurobiol (2016) 0.85
Use of enterally delivered angiotensin II type Ia receptor antagonists to reduce the severity of colitis. Dig Dis Sci (2011) 0.84
Resection of the nerves bundle from the sphenopalatine ganglia tend to increase the infarction volume following middle cerebral artery occlusion. Neurol Sci (2010) 0.83
Neuroprotective potentials of candesartan, atorvastatin and their combination against stroke induced motor dysfunction. Inflammopharmacology (2011) 0.83
Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes. PLoS One (2010) 0.82
CV-11974, angiotensin II type I receptor antagonist, reduces the severity of indomethacin-induced rat enteritis. Dig Dis Sci (2007) 0.82
Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro. Biochem Biophys Res Commun (2007) 0.79
Prevention and intervention studies with telmisartan, ramipril and their combination in different rat stroke models. PLoS One (2011) 0.79
Compromised regulation of tissue perfusion and arteriogenesis limit, in an AT1R-independent fashion, recovery of ischemic tissue in Cx40(-/-) mice. Am J Physiol Heart Circ Physiol (2013) 0.79
Blockade of Central Angiotensin II AT1 Receptor Protects the Brain from Ischemia/Reperfusion Injury in Normotensive Rats. Iran J Med Sci (2014) 0.75
Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important? Naunyn Schmiedebergs Arch Pharmacol (2017) 0.75
T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Arterioscler Thromb Vasc Biol (2008) 5.44
Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med (2005) 4.84
Quantitative real-time RT-PCR data analysis: current concepts and the novel "gene expression's CT difference" formula. J Mol Med (Berl) (2006) 4.00
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study. Circulation (2007) 3.59
Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation (2004) 2.64
A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res (2006) 2.50
Protective arms of the renin-angiotensin-system in neurological disease. Clin Exp Pharmacol Physiol (2013) 2.18
The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res (2007) 2.00
The beta-lactam antibiotic, ceftriaxone, dramatically improves survival, increases glutamate uptake and induces neurotrophins in stroke. J Hypertens (2008) 1.91
Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats. J Hypertens (2008) 1.81
Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press (2003) 1.79
Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein. Arterioscler Thromb Vasc Biol (2004) 1.75
Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation (2008) 1.72
PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin. Hypertension (2005) 1.60
Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes (2005) 1.58
Chronic treatment with losartan results in sufficient serum levels of the metabolite EXP3179 for PPARgamma activation. Hypertension (2009) 1.54
Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J (2005) 1.54
Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension (2010) 1.50
Angiotensin receptor blockers: therapeutic targets and cardiovascular protection. Blood Press (2005) 1.49
Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens (2004) 1.48
Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol (2003) 1.46
High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens (2004) 1.43
Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis. J Hypertens (2014) 1.40
Chronic treatment with a low dose of lithium protects the brain against ischemic injury by reducing apoptotic death. Stroke (2003) 1.40
Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes (2007) 1.39
Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma. PLoS Genet (2008) 1.35
RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol (2008) 1.34
Acidic pH and capsaicin activate mechanosensitive group IV muscle receptors in the rat. Pain (2004) 1.27
Effects of early life stress on adult male aggression and hypothalamic vasopressin and serotonin. Eur J Neurosci (2006) 1.27
PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol Sci (2007) 1.20
Excitatory and modulatory effects of inflammatory cytokines and neurotrophins on mechanosensitive group IV muscle afferents in the rat. Pain (2005) 1.19
Non-peptide AT2-receptor agonists. Curr Opin Pharmacol (2010) 1.15
Cardiac c-kit+AT2+ cell population is increased in response to ischemic injury and supports cardiomyocyte performance. Stem Cells (2009) 1.15
Novel therapeutic targets for hypertension. Nat Rev Cardiol (2010) 1.13
Sex-specific influence of angiotensin type 2 receptor stimulation on renal function: a novel therapeutic target for hypertension. Hypertension (2011) 1.12
Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol (2007) 1.10
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol (2010) 1.10
Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT2 receptor and the transcription factor NF-kappaB. FASEB J (2003) 1.10
AT2 receptor agonists: hypertension and beyond. Curr Opin Nephrol Hypertens (2012) 1.09
Identification of noncytotoxic and IL-10-producing CD8+AT2R+ T cell population in response to ischemic heart injury. J Immunol (2010) 1.08
Direct angiotensin II type 2 receptor stimulation in Nω-nitro-L-arginine-methyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling. Hypertension (2012) 1.07
Adenosine triphosphate as a stimulant for nociceptive and non-nociceptive muscle group IV receptors in the rat. Neurosci Lett (2003) 1.05
Circulating angiotensin converting enzyme activity is correlated with muscle strength. Med Sci Sports Exerc (2005) 1.05
Sex differences in physiological cardiac hypertrophy are associated with exercise-mediated changes in energy substrate availability. Am J Physiol Heart Circ Physiol (2011) 1.04
Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke. J Hypertens (2007) 1.03
Genetic kininogen deficiency contributes to aortic aneurysm formation but not to atherosclerosis. Physiol Genomics (2004) 1.02
PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovasc Diabetol (2010) 1.02
Prolactin prevents chronic stress-induced decrease of adult hippocampal neurogenesis and promotes neuronal fate. J Neurosci (2009) 1.02
Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat. J Cereb Blood Flow Metab (2004) 1.02
Liver-specific peroxisome proliferator-activated receptor alpha target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes (2008) 1.01
The intracerebral application of the PPARgamma-ligand pioglitazone confers neuroprotection against focal ischaemia in the rat brain. Eur J Neurosci (2005) 1.00
The past, present and future of angiotensin II type 2 receptor stimulation. J Renin Angiotensin Aldosterone Syst (2009) 0.99
Sensitization of rat dorsal horn neurons by NGF-induced subthreshold potentials and low-frequency activation. A study employing intracellular recordings in vivo. Brain Res (2007) 0.99
Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren. J Hypertens (2008) 0.99
Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain. Brain Res (2008) 0.98
No association between Angiotensin Converting Enzyme (ACE) gene variation and endurance athlete status in Kenyans. Comp Biochem Physiol A Mol Integr Physiol (2005) 0.98
Angiotensin receptor blockers and cerebral protection in stroke. J Hypertens Suppl (2006) 0.97
The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam Clin Pharmacol (2009) 0.96
Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats. J Hypertens (2002) 0.95
Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther (2002) 0.94
Peroxisome-proliferator-activated receptors gamma and peroxisome-proliferator-activated receptors beta/delta and the regulation of interleukin 1 receptor antagonist expression by pioglitazone in ischaemic brain. J Hypertens (2010) 0.93
AT2-receptor stimulation enhances axonal plasticity after spinal cord injury by upregulating BDNF expression. Neurobiol Dis (2012) 0.93
Cardiac inflammation after local irradiation is influenced by the kallikrein-kinin system. Cancer Res (2012) 0.93
Low inborn anxiety correlates with high intermale aggression: link to ACTH response and neuronal activation of the hypothalamic paraventricular nucleus. Horm Behav (2006) 0.93
Transition from atherosclerosis to aortic aneurysm in humans coincides with an increased expression of RAS components. Atherosclerosis (2009) 0.92
Neuroprotection with angiotensin receptor antagonists: a review of the evidence and potential mechanisms. Am J Cardiovasc Drugs (2005) 0.91
Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation. J Hypertens (2008) 0.91
Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation. J Neurochem (2005) 0.91
Peroxisome proliferator-activated receptorsgamma (PPARgamma) differently modulate the interleukin-6 expression in the peri-infarct cortical tissue in the acute and delayed phases of cerebral ischaemia. Eur J Neurosci (2008) 0.91
The angiotensin AT2 receptor in left ventricular hypertrophy. J Hypertens (2010) 0.90
Endothelial dysfunction and its role in diabetic vascular disease. Endocrinol Metab Clin North Am (2006) 0.89
Aldosterone synthase inhibitors in cardiovascular and renal diseases. Nephrol Dial Transplant (2014) 0.89
Impact of the AT(2) receptor agonist C21 on blood pressure and beyond. Curr Hypertens Rep (2012) 0.89
Contribution of bradykinin and nitric oxide to AT2 receptor-mediated differentiation in PC12 W cells. J Neurochem (2003) 0.89
Acute blood pressure effects and chronic hypotensive action of calcimimetics in uremic rats. J Am Soc Nephrol (2006) 0.88
Direct stimulation of angiotensin II type 2 receptor enhances spatial memory. J Cereb Blood Flow Metab (2011) 0.88
AT(2) receptor and tissue injury: therapeutic implications. Curr Hypertens Rep (2014) 0.87
Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. Hypertension (2005) 0.87
Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage. Hypertens Res (2009) 0.87
The possible role of the NO-cGMP pathway in nociception: different spinal and supraspinal action of enzyme blockers on rat dorsal horn neurones. Pain (2005) 0.87